Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

H. Lee Moffitt Cancer Center and Research Institute: Clinical Trials & FDA Approval Profile

H. Lee Moffitt Cancer Center and Research Institute (Global / Institutional) sponsors 90 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 63 active protocols (35 recruiting now), 12 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)16.7%
Median Closed Enrollment vs National (145 pts)22 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for H. Lee Moffitt Cancer Center and Research Institute
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)90
Active Pipeline (Recruiting Now)63 (35)
Completed vs Stopped Early12 / 15 (16.7%)
Median Closed Actual Enrollment22 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With H. Lee Moffitt Cancer Center and Research Institute
Hospital Research SiteLocationShared Protocols
Moffitt Cancer CenterTampa, FL87
Ohio State University Comprehensive Cancer CenterColumbus, OH4
Roswell Park Comprehensive Cancer CenterBuffalo, NY3

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by H. Lee Moffitt Cancer Center and Research Institute
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06701812Digoxin Medulloblastoma StudyPhase IIRECRUITING
NCT06745882Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLCPhase IIRECRUITING
NCT04388839Evolutionary Therapy for RhabdomyosarcomaPhase IIACTIVE NOT RECRUITING
NCT03610971Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase InhibitorsPhase IIACTIVE NOT RECRUITING

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Moffitt Cancer Center across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the H. Lee Moffitt Cancer Center and Research Institute Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI